Holen Sie sich die Stockscreener-App
13.70
2.14%
0.36
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com
MSN Money - MSN
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Earnings Preview: EyePoint to Report Financial Results Pre-market on May 06 - Moomoo
Is EyePoint (NASDAQ:EYPT) In A Good Position To Invest In Growth? - Moomoo
Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday - MarketBeat
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - Yahoo Finance
EyePoint (NASDAQ: EYPT) plans virtual 2026 meeting and larger equity pool - Stock Titan
EyePoint, Inc. Income Statement – NASDAQ:EYPT - TradingView
EYPT (EyePoint Inc.) shares rise 2.02 percent despite wider Q4 2025 loss and 27.5 percent year over year revenue drop.Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Top Executive Makes Strategic Move With EyePoint Pharmaceuticals Stock - TipRanks
Understanding Momentum Shifts in (EYPT) - Stock Traders Daily
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares By Investing.com - Investing.com South Africa
EyePoint CMO Ramiro Ribeiro sells $36,555 in company shares - Investing.com
[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan
Is EyePoint (EYPT) stock reversing trend (Bullish Sentiment) 2026-04-20Fast Rising Picks - Cổng thông tin điện tử Tỉnh Sơn La
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
[144] EyePoint, Inc. SEC Filing - Stock Titan
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 150% Potential Upside in the Booming Biotech Sector - DirectorsTalk Interviews
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Eyepoint reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
EyePoint hires 14 employees, grants 362,500 stock options - Stock Titan
JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway - TipRanks
EyePoint posts April 2026 investor presentation; DURAVYU Phase 3 updates, cash runway into Q4 2027 - TradingView
DURAVYU Phase 3 plans and cash runway outlined by EyePoint (EYPT) - Stock Titan
Will EyePoint (EYPT) Stock Miss Expectations | Price at $14.00, Down 1.34%Social Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Avoiding Lag: Real-Time Signals in (EYPT) Movement - Stock Traders Daily
Recap Report: What is the long term forecast for EyePoint Pharmaceuticals Inc stockQuarterly Trade Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Stocks to watch: EyePoint sees relative strength rating rise to 92 - MSN
What are analysts saying about EyePoint (EYPT) Stock | Price at $13.57, Up 3.51%Community Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Aug Reactions: What are analysts price targets for EyePoint Pharmaceuticals IncPrice Action & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7%Time to Sell? - marketbeat.com
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com
EyePoint, Inc. (EYPT) stock price, news, quote and history - Yahoo Finance UK
Parkman Healthcare Partners LLC's EyePoint Inc(EYPT) Holding History - GuruFocus
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com
Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
STU:PV3B PB Ratio: 3.51 — 21% Below Median - GuruFocus
EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI
EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - capital.com
EyePoint Inc : Jefferies Assumes Coverage Wit - Moomoo
Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily
Stock List: Research Stocks from Around the World - gurufocus.com
Tech Rally: What is the PEG ratio of EyePoint Pharmaceuticals Inc2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - ca.investing.com
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Yahoo Finance
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):